Diaceutics PLC Directorate Change (4359J)
December 22 2020 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 4359J
Diaceutics PLC
22 December 2020
Diaceutics PLC
("Diaceutics" or the "Company" or the "Group")
Directorate change
Diaceutics PLC (AIM: DXRX), announces the resignation of Julie
Goonewardene as Non-Executive Chair. Julie will step down on 31
December 2020. Having been with Diaceutics for almost 10 years
Julie has, with the support of the Board, decided to step down.
Julie Goonewardene commented : "It has been my pleasure and
privilege to work with the Diaceutics team for the better part of a
decade. I have enjoyed the journey of helping guide the Company
from a small Irish boutique consultancy to a global publicly traded
data enabled platform firm. My goal has always been to see the
Company reach the important milestone of launching its
transformative platform, DXRX, and together we have achieved this
objective. DXRX has great potential and I look forward to seeing
how it transforms the diagnostics industry."
Peter Keeling, Chief Executive Officer of Diaceutics said:
"Julie has been a trusted partner and friend through all of the
growth stages of the Company and a key contributor to our most
successful strategies right up to the successful IPO in March 2019.
On behalf of the Board, we would like to thank Julie for all her
hard work and the support she has given us during her time with
Diaceutics. She has been a valued member of the Group, and we are
sad to see her go."
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0) 20 7391 8900
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - a proprietary
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. The Company,
listed on the AIM Market of the London Stock Exchange, has created
commercially useful data sets for every precision medicine that has
come to market. We have built the world's largest repository of
diagnostic testing data with a growing network of 2500 labs in 51
countries. www.diaceutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKKDBNOBDDOBB
(END) Dow Jones Newswires
December 22, 2020 02:00 ET (07:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024